Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for AF Recurrence in Structural Heart Disease
NCT06168994Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Feb 2024
- Primary completion
- Sep 2026
- Sponsor
- Assiut University
- Modality
- Orthosteric Ligands
- Drugs
- eplerenone
- Conditions
- Atrial fibrillation (AFib)
01
Overview
Phase 4, randomised, single-blind trial of eplerenone in Atrial fibrillation (AFib) (2 arms), sponsored by Assiut University. Primary endpoint: Recurrence of Atrial Fibrillation at 31 months. Planned start Feb 2024; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Amiodarone Only
Standard Amiodarone therapy
Eplerenone + Amiodarone
Amiodarone plus Eplerenone
03
Who it enrols
Patients with paroxysmal AF reverted to sinus rhythm and structural heart disease (LVEF >= 50%). Excludes patients on MRBs, beta blockers, or non-DHP CCBs, and those with severe renal/liver disease or thyroid dysfunction.
04
Endpoints
Primary
Recurrence of Atrial Fibrillation
Beyond the preview
Go deeper on NCT06168994.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168994.